Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Part D "Trial Size" Scripts Proposed, With Drug Tolerance And Waste In Mind

Executive Summary

A proposal to offer "trial size" prescriptions for Medicare Part D beneficiaries trying new medications to treat chronic conditions already has garnered some mixed reactions

You may also be interested in...



CMS Takes Second Shot At Mandating “Trial Size” Prescriptions For Part D; Estimates Savings At $2.5 Billion By 2018

CMS once again has proposed mandating that Medicare Part D prescription drug plan sponsors offer a “trial size” of first-fill prescriptions for medications treating chronic conditions and, in a step further than the previous effort, mandated that the cost-sharing be prorated based on the daily cost of the drug.

CMS Takes Second Shot At Mandating “Trial Size” Prescriptions For Part D; Estimates Savings At $2.5 Billion By 2018

CMS once again has proposed mandating that Medicare Part D prescription drug plan sponsors offer a “trial size” of first-fill prescriptions for medications treating chronic conditions and, in a step further than the previous effort, mandated that the cost-sharing be prorated based on the daily cost of the drug.

CMS Proposes "Trial Sizes" Of Prescriptions To Curb Waste Of Unused Drugs In Part D

Under a plan outlined in a draft Medicare Part D "call letter," patients receiving a new prescription for a drug previously unused by them would be able to receive an initial trial size supply of no more than seven to 14 days.

Topics

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel